Bicycle Therapeutics Signs 15-Year Uranium Supply Contract with UK Nuclear Decommissioning Authority
Bicycle Therapeutics plc announced the execution of a 15-year contract, with an option to renew, with the UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium (RepU). This agreement is intended to support the company's wholly owned radiopharmaceutical pipeline by providing a potentially sustainable supply of lead-212 (212Pb). The company also disclosed partnerships with the United Kingdom National Nuclear Laboratory to scale up the extraction of thorium-228 from RepU, and with SpectronRx to develop a bespoke 212Pb generator, with initial quantities of 212Pb successfully produced.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215037659) on December 16, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。